Viking Therapeutics (NASDAQ:VKTX – Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06, Briefing.com reports. During the same quarter in the previous year, the firm posted ($0.19) earnings per share.
Viking Therapeutics Price Performance
Shares of VKTX opened at $64.68 on Friday. The company has a 50-day simple moving average of $55.75 and a two-hundred day simple moving average of $55.89. The firm has a market capitalization of $7.13 billion, a PE ratio of -69.55 and a beta of 1.03. Viking Therapeutics has a one year low of $8.28 and a one year high of $99.41.
Insiders Place Their Bets
In other news, COO Marianna Mancini sold 281,425 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $78.66, for a total value of $22,136,890.50. Following the completion of the transaction, the chief operating officer now owns 348,508 shares in the company, valued at approximately $27,413,639.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Viking Therapeutics news, COO Marianna Mancini sold 281,425 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the completion of the transaction, the chief operating officer now owns 348,508 shares of the company’s stock, valued at $27,413,639.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Greg Zante sold 66,756 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the sale, the chief financial officer now owns 174,854 shares in the company, valued at approximately $13,059,845.26. The disclosure for this sale can be found here. Company insiders own 4.70% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Stock Report on Viking Therapeutics
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Read More
- Five stocks we like better than Viking Therapeutics
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Is Now the Time to Invest? ServiceNow Stock Sent to New Highs
- 5 discounted opportunities for dividend growth investors
- Leading Healthcare Provider Stock Soars on Earnings Beat
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.